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Tocilizumab therapy for unresponsive pulmonary arterial hypertension in
a patient with Takayasu arteritis
A Ferrante1, F Ciccia1, G Guggino1, D Colomba2, G Triolo1
Biomedical Department of Internal Medicine, 1Section of Rheumatology and 2Section of Cardioangiology, University of Palermo, Italy
A 46-year-old female Caucasian patient was referred to
our unit with upper extremity claudication, dyspnoea
[New York Heart Association (NYHA) Class III], and
weight loss. On physical examination, asymmetry in
upper limb blood pressure and an abolished right radial
pulse was demonstrated. C-reactive protein (CRP) level
was 15 mg/dL and the 6-minute walking distance
(6MWD) was 380 m. Doppler ultrasound imaging
revealed stenosis of the right subclavian and left carotid
arteries. Magnetic resonance angiography (MRA)
showed circumferential wall thickening of the aorta
and the subclavian and carotid arteries, with mural
enhancement. Positron emission tomography–computed
tomography (PET/CT) was also performed, demonstrat-
ing the presence of a high diffuse vascular uptake. A
diagnosis of Takayasu arteritis (TA) was made accord-
ing to American College of Rheumatology (ACR) cri-
teria (1). Pulmonary function tests were normal but the
diffusing capacity of the lung for carbon monoxide
(DLCO) was reduced (50% percentage of predicted).
Enlargement of the cardiac silhouette without evidence
of parenchymal lung disease was observed on chest
radiography and high-resolution chest CT. Pulmonary
hypertension was suspected by transthoracic echocardio-
graphy and conﬁrmed by cardiac catheterization. The
central venous pressure was 6 mmHg, the pulmonary
artery pressure (PAP) was 61/24 mmHg with a mean
value (mPAP) of 44 mmHg, and the pulmonary capillary
wedge pressure (PCWP) was 7 mmHg with a high
vascular resistance of 860 dyn.s/cm5. Treatment was
established and consisted of oral prednisone (1 mg/kg),
methotrexate (20 mg/week), bosentan (125 mg twice
daily) plus, after 3 months, sildenaﬁl (120 mg/day).
Although a reduction in fatigue and normalization of
inﬂammatory markers were observed, there was no
improvement in clinical and haemodynamic parameters
after 6 months (Figure 1). For this reason, after getting
informed consent, monthly treatment with intravenous
tocilizumab (8 mg/kg) was started. Eight weeks later an
improvement in disease activity with a steroid sparing
drug effect and a signiﬁcant amelioration of functional
class (NYHA II) were observed. Three months later,
transthoracic echocardiography showed a signiﬁcant
reduction in tricuspid regurgitation peak velocity (3.1
m/s) and 4 months later right-heart catheterization
showed a signiﬁcant reduction in mPAP (28 mmHg)
(Figure 1). After 6 months of treatment, echocardio-
graphic and haemodynamic parameters were completely
normalized (Figure 1).
To our knowledge this is the ﬁrst case of TA and
PAH successfully treated with the interleukin (IL)-6
blocking agent tocilizumab. TA is a chronic vasculitis
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Figure 1. Clinical and haemodynamic para-
meters. mPAP, mean pulmonary artery pressure;
TRVmax, maximal velocity of tricuspid regurgi-
tation; PVR, pulmonary vascular resistance;
NYHA I, II, III, New York Heart Association
Class I, II, III.
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of unknown aetiology, predominantly affecting the
aorta and its branches. TA may be complicated by
life-threatening pulmonary arterial hypertension
(PAH) (2). Treatment with glucocorticoids and di-
sease-modiﬁed anti-rheumatic drugs (DMARDs)
appears to be partially effective (3). Strong expression
of IL-6 in the aorta and elevated serum IL-6 levels
have been reported in patients with TA and correlated
with disease activity (4). Accumulating evidence also
shows, in animal models, that lung-speciﬁc overex-
pression of IL-6 resulted in increased pulmonary vas-
cular resistance (PVR) and pathological lesions similar
to that seen in patients with PAH, including distal
arteriolar muscularization, plexogenic arteriopathy,
and periarteriolar inﬁltration of T cells (5). Altogether,
these ﬁndings seem to indicate that IL-6 directly or
indirectly promotes proliferation of both smooth mus-
cle cells and endothelial cells, and that the IL-6 block-
ing could represent an ideal therapeutic target in TA
patients with PAH (5–8). The rapidity of effectiveness
of tocilizumab appears surprising in this case and
could be related to an initial effect on vascular inﬂam-
mation, as indicated by the fast clinical and biological
effects observed in our and other studies (9, 10).
References
1. Arend WP, Michel BA, Bloch DA, Hunder GG, Calabrese LH,
Edworthy SM, et al. The American College of Rheumatology 1990
criteria for the classiﬁcation of Takayasu arteritis. Arthritis Rheum
1990;33:1129–34.
2. Wang X, Dang A, Cheng B, Lin N, Liu Q. Takayasu arteritis-asso-
ciated pulmonary hypertension. J Rheumatol 2015;42: 495–502.
3. Arnaud L, Haroche J, Limal N, Toledano D, Gambotti L, Coste-
doat Chalumeau N, et al. Takayasu arteritis in France: a single-
center retrospective study of 82 cases comparing white, North
African, and black patients. Medicine (Baltimore) 2010;89:1–17.
4. Arnaud L, Haroche J, Mathian A, Gorochov G, Amoura Z. Pathogen-
esis of Takayasu’s arteritis: a 2011 update. Autoimmun Rev
2011;11:61–7.
5. Steiner MK, Syrkina OL, Kolliputi N, Mark EJ, Hales CA,
Waxman AB. Interleukin-6 overexpression induces pulmonary
hypertension. Circ Res 2009;104:236–44.
6. Cool CD, Kennedy D, Voelkel NF, Tuder RM. Pathogenesis and
evolution of plexiform lesions in pulmonary hypertension asso-
ciated with scleroderma and human immunodeﬁciency virus infec-
tion. Human Pathology 1997;28:424–42.
7. Salvarani C, Magnani L, CatanosoMG, Pipitone N, Versari A, Dardani
L, et al. Rescue treatment with tocilizumab for Takayasu arteritis
resistant to TNF-α blockers. Clin Exp Rheumatol 2012;30:S90–3.
8. El Kasmi KC, Pugliese SC, Riddle SR, Poth JM, Anderson AL,
Frid MG, et al. Adventitial ﬁbroblasts induce a distinct proinﬂam-
matory/proﬁbrotic macrophage phenotype in pulmonary hyperten-
sion. J Immunol 2014;193:597–609.
9. Abisror N, Mekinian A, Lavigne C, Vandenhende MA, Soussan M,
Fain O. Tocilizumab in refractory Takayasu arteritis: a case series and
updated literature review. Autoimmun Rev 2013;12:1143–9.
10. Osman M, Emery D, Yacyshyn E. Tocilizumab for treating
Takayasu’s arteritis and associated stroke: a case series and
updated review of the literature. J Stroke Cerebrovasc Dis
2015;24:1291–8.
Angelo Ferrante, Biomedical Department of Internal Medicine, Section
of Rheumatology, University of Palermo, Piazza delle Cliniche 2, I-
90127 Palermo, Italy.
E-mail: angelo.ferrante@unipa.it
Accepted 5 October 2015
Anakinra for the treatment of familial Mediterranean fever-associated
spondyloarthritis
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Department of Internal Medicine, Division of Rheumatology, Gazi University Faculty of Medicine, Ankara, Turkey
Familial Mediterranean fever (FMF) is an autosomal
recessive disease characterized by recurrent febrile
attacks of serositis and arthritis. FMF is caused by muta-
tions in the Mediterranean fever (MEFV) gene and resul-
tant excessive interleukin (IL)-1 production. About 10%
of FMF patients have spondyloarthritis (1, 2). We report
an interesting case of a patient with FMF who responded
well to anakinra but not to anti-tumour necrosis factor
(TNF) agents.
A 39-year-old female patient presented to our out-
patient clinic with inﬂammatory lower back pain 3
years ago. Two years previously she had been diagnosed
with FMF. She had recurrent attacks of fever, peritonitis,
pleuritis, and arthritis and a single heterozygous V726A
mutation of the MEFV gene was demonstrated. She was
on colchicine treatment since the diagnosis of FMF. Her
erythrocyte sedimentation rate (ESR) and C-reactive
protein (CRP) levels were 39 mm/h and 12.8 mg/L,
respectively. Human leucocyte antigen (HLA)-B27 was
negative. Sacroiliac magnetic resonance imaging (MRI)
revealed bony sclerosis, signs of chronic sacroiliitis, and
slight oedema at the sacroiliac joint. Bone scintigraphy
showed bilateral sacroileitis. She was prescribed diclo-
fenac and sulfasalazine, which were ineffective. Her
axial pain and morning stiffness continued despite
6 months of treatment with adalimumab and meloxicam,
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